Gabapentin in Phantom and Stump Pain

Phase 4CompletedNCT00169013

Danish Pain Research Center

Overview

To investigate whether gabapentin can prevent phantom and stump pain after amputation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Amputation of Lower Limb

Interventions

GabapentinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1\. Amputation of crus or femur Exclusion Criteria: 1. Patients who cannot cooperate 2. Fertile women without sufficient contraceptives 3. Allergy to gabapentin 4. Earlier amputation of the same limb except toes 5. Serious lever, kidney, cardiac, respiratory, haematological disease.-

Locations (1)

Danish Pain Research Center, Aarhus University Hospital

Aarhus, Denmark

Outcomes

Primary Outcomes

Primary outcome measures:

Number of patients with phantom and stump pain 30 days and 6 months after amputation

Average intensity of stump and phantom pain 30 days and 6 months after amputation

Secondary Outcomes

Secondary outcome measures:

Prevalence and severity of phantom and stump pain at controls day 7, 14 and 30, and 3 and 6 months

McGill Pain Questionnaire day 7, 14 and 30, and 3 and 6 months

Concurrent pain medication at day 7, 14 and 30, and 3 and 6 months

Brush evoked allodynia, wind up like pain to repetitive pinprick, pressure pain threshold at day 14 and 30.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.